Climb Bio (CLYM) Change in Account Payables (2020 - 2026)
Climb Bio (CLYM) posted Change in Account Payables of -$1.4 million for Q1 2026, down 178.63% on a QoQ basis from $1.8 million in Q4 2025, and down 2056.94% year-over-year from $72000.0 in Q1 2025.
Climb Bio (CLYM) Change in Account Payables (2020 - 2026) Analysis & Trends
Climb Bio's Change in Account Payables history runs 7 years deep, the most recent figure standing at -$1.4 million for Q1 2026.
- Quarterly Change in Account Payables fell 2056.94% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83000.0 (up 109.11% YoY) and the FY2025 annual result came in at $1.6 million, up 262.41% from the prior year.
- Change in Account Payables was -$1.4 million for Q1 2026 at Climb Bio, down from $1.8 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.8 million in Q4 2025 and bottomed at -$1.4 million in Q1 2026.
- A 5-year average of -$126294.1 and a median of $14000.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 608.7% — and 2024, when it slumped 8528.57%.
- Climb Bio's Change in Account Payables stood at -$744000.0 in 2022, then gained by 9.68% to -$672000.0 in 2023, then soared by 161.61% to $414000.0 in 2024, then jumped by 332.85% to $1.8 million in 2025, then sank by 178.63% to -$1.4 million in 2026.
- Business Quant data shows CLYM's Change in Account Payables at -$1.4 million in Q1 2026, $1.8 million in Q4 2025, and -$393000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | -1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.41 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | 1.79 Mn |
| Dec 31, 2025 | 1.79 Mn |
| Sep 30, 2025 | -393,000.00 |
| Sep 30, 2025 | -393,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Dec 31, 2024 | 414,000.00 |
| Dec 31, 2024 | 414,000.00 |
| Sep 30, 2024 | -217,000.00 |
| Sep 30, 2024 | -217,000.00 |
| Jun 30, 2024 | -1.18 Mn |
| Jun 30, 2024 | -1.18 Mn |
| Mar 31, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | -672,000.00 |
| Dec 31, 2023 | -672,000.00 |